<DOC>
	<DOC>NCT00998686</DOC>
	<brief_summary>The purpose of this study is to demonstrate the safety and tolerability of dutogliptin over 52 weeks.</brief_summary>
	<brief_title>Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Completion of all required visits of a qualifying Phase 3 core protocol Current treatment of Type 2 diabetes mellitus as in PHX1149PROT302 Any condition, disease, disorder or clinically relevant laboratory abnormality which, in the opinion of the investigator, would jeopardize the patient's appropriate participation in this study or obscure the effects of treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>diabetes</keyword>
	<keyword>DPP4 inhibitor</keyword>
	<keyword>dutogliptin</keyword>
</DOC>